Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A.
Ontology highlight
ABSTRACT: The normally antiviral enzyme APOBEC3A1-4 is an endogenous mutagen in many different human cancers5-7, where it becomes hijacked to fuel tumor evolvability. APOBEC3A's single-stranded DNA C-to-U editing activity1,8 results in multiple mutagenic outcomes including signature single-base substitution mutations (isolated and clustered), DNA breakage, and larger-scale chromosomal aberrations5-7. Transgenic expression in mice demonstrates its tumorigenic potential9. APOBEC3A inhibitors may therefore comprise a novel class of anti-cancer agents that work by blocking mutagenesis, preventing tumor evolvability, and lessening detrimental outcomes such as drug resistance and metastasis. Here we reveal the structural basis of competitive inhibitio
SUBMITTER: Harjes S
PROVIDER: S-EPMC9949147 | biostudies-literature | 2023 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA